Vol 8, No 4 (2019)
Research paper
Published online: 2019-09-19

open access

Page views 1522
Article views/downloads 854
Get Citation

Connect on Social Media

Connect on Social Media

Probiotics and smectite absorbent gel formulation reduce liver stiffness, transaminase and cytokine levels in NAFLD associated with type 2 diabetes: a randomized clinical study

Nazarii Kobyliak1, Ludovico Abenavoli2, Galyna Mykhalchyshyn1, Tetyana Falalyeyeva3, Olena Tsyryuk3, Liudmyla Kononenko1, Dmytro Kyriienko14, Iuliia Komisarenko1
Clin Diabetol 2019;8(4):205-214.

Abstract

Introduction. In double-blind single center randomized clinical trial (RCT), the efficacy of alive probiotics sup­plementation with smectite gel vs. placebo in type 2 diabetes patient with non-alcoholic fatty liver disease (NAFLD) detected on ultrasonography (US) were studied.

Material and methods. A total of 50 patients met the criteria for inclusion. They were randomly assigned to receive Symbiter Forte combination of probiotic biomass with smectite gel (250 mg) or placebo for 8-weeks. The primary main outcomes were the change in fatty liver index (FLI) and liver stiffness (LS) meas­ured by shear wave elastography (SWE). Secondary outcomes were the changes in transaminases activity, serum lipids and cytokines levels.

Results. All subjects completed the study and received more than 90% of prescribed sachets. In respect to our primary endpoints, FLI and LS insignificant de­crease in both interventional and placebo groups. However, when we compare mean changes across groups from baseline, expressed in absolute values, the reduction of both LS (–0.254 ± 0.85 vs. 0.262 ± 0.77; p = 0.031) were observed. Analysis of sec­ondary outcomes showed that co-administration of probiotic with smectite lead to significant reduction of alanine aminotransferase (ALT), aspartate amino­transferase (AST), total cholesterol, IL-1b, and tumor necrosis factor (TNF-a) after 8 weeks.

Conclusion. In this RCT, we confirmed previously re­ported animal data, showing that co-administration of probiotic with smectite manifested with reduction of LS, liver transaminases and chronic systemic inflam­mation.

Article available in PDF format

View PDF Download PDF file

References

  1. Nascimbeni F, Pais R, Bellentani S, et al. From NAFLD in clinical practice to answers from guidelines. J Hepatol. 2013; 59(4): 859–871.
  2. Abenavoli L, Milic N, Di Renzo L, et al. Metabolic aspects of adult patients with nonalcoholic fatty liver disease. World J Gastroenterol. 2016; 22(31): 7006–7016.
  3. Bellentani S. The epidemiology of non-alcoholic fatty liver disease. Liver Int. 2017; 37 Suppl 1: 81–84.
  4. Musso G, Gambino R, Cassader M, et al. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med. 2011; 43(8): 617–649.
  5. Mykhalchyshyn G, Kobyliak N, Bodnar P. Diagnostic accuracy of acyl-ghrelin and it association with non-alcoholic fatty liver disease in type 2 diabetic patients. J Diabetes Metab Disord. 2015; 14: 44.
  6. Kyriachenko Y, Falalyeyeva T, Korotkyi O, et al. Crosstalk between gut microbiota and antidiabetic drug action. World J Diabetes. 2019; 10(3): 154–168.
  7. World Health Organization and Food & Agriculture Organization. Guidelines for the Evaluation of Probiotics in Food; Report of a Joint FAO/WHO Working Group on Drafting Guidelines for the Evaluation of Probiotics in Food; FAO/WHO: London, ON, Canada, 2002; Available online: ftp://ftp.fao.org/es/esn/food/wgreport2.pdf.
  8. Federico A, Dallio M, Godos J, et al. Targeting gut-liver axis for the treatment of nonalcoholic steatohepatitis: translational and clinical evidence. Transl Res. 2016; 167(1): 116–124.
  9. Wu TR, Lin CS, Chang CJ, et al. Gut commensal Parabacteroides goldsteinii plays a predominant role in the anti-obesity effects of polysaccharides isolated from Hirsutella sinensis. Gut. 2019; 68(2): 248–262.
  10. Cani PD, de Vos WM. Next-Generation beneficial microbes: the case of Akkermansia Muciniphila. Front Microbiol. 2017; 8: 1765.
  11. Kobyliak N, Falalyeyeva T, Virchenko O, et al. Comparative experimental investigation on the efficacy of mono- and multiprobiotic strains in non-alcoholic fatty liver disease prevention. BMC Gastroenterol. 2016; 16: 34.
  12. Kobyliak N, Falalyeyeva T, Beregova T, et al. Probiotics for experimental obesity prevention: focus on strain dependence and viability of composition. Endokrynol Pol. 2017; 68(6): 659–667.
  13. Kobyliak N, Falalyeyeva T, Bodnar P, et al. Probiotics supplemented with omega-3 fatty acids are more effective for hepatic steatosis reduction in an animal model of obesity. Probiotics Antimicrob Proteins. 2017; 9(2): 123–130.
  14. Dupont C, Vernisse B. Anti-diarrheal effects of diosmectite in the treatment of acute diarrhea in children: a review. Paediatr Drugs. 2009; 11(2): 89–99.
  15. Weese JS, Cote NM, deGannes RVG. Evaluation of in vitro properties of di-tri-octahedral smectite on clostridial toxins and growth. Equine Vet J. 2003; 35(7): 638–641.
  16. Faure C. Role of antidiarrhoeal drugs as adjunctive therapies for acute diarrhoea in children. Int J Pediatr. 2013; 2013: 612403.
  17. González R, de Medina FS, Martínez-Augustin O, et al. Anti-inflammatory effect of diosmectite in hapten-induced colitis in the rat. Br J Pharmacol. 2004; 141(6): 951–960.
  18. Mahraoui L, Heyman M, Plique O, et al. Apical effect of diosmectite on damage to the intestinal barrier induced by basal tumour necrosis factor-alpha. Gut. 1997; 40(3): 339–343.
  19. Kobyliak N, Falalyeyeva T, Boyko N, et al. Probiotics and nutraceuticals as a new frontier in obesity prevention and management. Diabetes Res Clin Pract. 2018; 141: 190–199.
  20. Kobyliak N, Abenavoli L, Falalyeyeva T, et al. Efficacy of probiotics and smectite in rats with non-alcoholic fatty liver disease. Ann Hepatol. 2018; 17(1): 153–161.
  21. Kobyliak N, Abenavoli L, Mykhalchyshyn G, et al. A multi-strain probiotic reduces the fatty liver index, cytokines and aminotransferase levels in NAFLD patients: evidence from a randomized clinical trial. J Gastrointestin Liver Dis. 2018; 27(1): 41–49.
  22. Kobyliak N, Abenavoli L, Falalyeyeva T, et al. Beneficial effects of probiotic combination with omega-3 fatty acids in NAFLD: a randomized clinical study. Minerva Med. 2018; 109(6): 418–428.
  23. Bedogni G, Miglioli L, Masutti F, et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006; 6(5): 33.
  24. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972; 18(6): 499–502.
  25. Montandon SA, Jornayvaz FR. Effects of antidiabetic drugs on gut microbiota composition. Genes (Basel). 2017; 8(10).
  26. Wu H, Esteve E, Tremaroli V, et al. Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug. Nat Med. 2017; 23(7): 850–858.
  27. Mofidi F, Poustchi H, Yari Z, et al. Synbiotic supplementation in lean patients with non-alcoholic fatty liver disease: a pilot, randomised, double-blind, placebo-controlled, clinical trial. Br J Nutr. 2017; 117(5): 662–668.
  28. Bailey SW. Summary of recommendations of AIPEA nomenclature committee on clay minerals. Clay Miner. 1980; 65: 1–7.